The LATITUDE Study: Long-Acting Therapy to Improve Treatment SUccess in Daily LifE

NCT03635788 · clinicaltrials.gov ↗

PHASE3

Phase

ACTIVE_NOT_RECRUITING

Status

456

Enrollment

NIH

Sponsor class

Conditions

HIV Infections

Interventions

DRUG: Standard of Care (SOC) Oral ART
DRUG: Oral RPV
DRUG: Oral CAB
DRUG: RPV-LA Loading Dose
DRUG: CAB-LA Loading Dose
DRUG: RPV-LA Maintenance Dose
DRUG: CAB-LA Maintenance Dose

Sponsor

National Institute of Allergy and Infectious Diseases (NIAID)

Collaborators

[object Object]